Drugs for Deafness, Dystonia, and Cerebral Hypomyelination (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 167)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Risperidone |
Approved, Investigational |
Phase 4 |
|
106266-06-2 |
5073 |
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
Belivon
BIDD:GT0262
Bio-0092
BRD-K53857191-001-04-5
BRN 4891881
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
Consta, risperdal
Consta, Risperdal
CPD000466323
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
Lopac-R-118
LS-134196
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
NCGC00015883-02
|
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R64,766
R-64,766
R64766
R-64766
R-64-766
Rispen
Risperdal
Risperdal (TN)
Risperdal consta
Risperdal Consta
Risperdal m-tab
Risperdal M-Tab
risperdone
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
risperidone
Risperidone
Rispéridone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
Sequinan
SMR000466323
SPBio_003078
Spiron
STK646402
TL8000230
UNII-L6UH7ZF8HC
|
|
2 |
|
Olanzapine |
Approved, Investigational |
Phase 4 |
|
132539-06-1 |
4585 |
Synonyms:
132539-06-1
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC1L1IHS
AC-665
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
Lanzac
Lilly brand of olanzapine
LS-152313
LY 170053
LY-170052
|
LY-170053
Midax
MLS000759457
MLS001165781
MLS001195646
MLS001424057
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
olanzapina
Olanzapina
olanzapine
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
olanzapinum
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa intramuscular
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa zydis
Zyprexa Zydis
|
|
3 |
|
Amantadine |
Approved |
Phase 4 |
|
768-94-5 |
2130 |
Synonyms:
1 Aminoadamantane
138576_ALDRICH
1-Adamantamine
1-adamantanamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-adamantylamine
1-Adamantylamine
1-aminoadamantane
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
665-66-7 (hydrochloride)
768-94-5
AB00514655
AbZ brand OF amantadine hydrochloride
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
Adamantamine
adamantan-1-amine
adamantan-1-ylamine
Adamantanamine
ADAMANTANE,1-AMINO
Adamantylamine
Adekin
AKOS000113994
AKOS000119324
AL, amantadin
Aliud brand OF amantadine sulfate
Alliance brand OF amantadine hydrochloride
Aman
Amant
Amanta
Amanta hci azu
Amanta sulfate azu
Amantadin al
Amantadin azu
Amantadin neuraxpharm
Amantadin ratiopharm
Amantadin stada
Amantadina
Amantadina [INN-Spanish]
Amantadina juventus
Amantadina llorente
amantadine
Amantadine
Amantadine (INN)
Amantadine [INN:BAN]
Amantadine base
Amantadine Base
Amantadine HCL
amantadine hydrochloride
Amantadine hydrochloride
Amantadine sulfate
Amantadinneuraxpharm
Amantadin-neuraxpharm
Amantadinratiopharm
Amantadin-ratiopharm
Amantadinum
Amantadinum [INN-Latin]
Amanta-hci-azu
AmantaHCIAZU
Amantasulfateazu
Amanta-sulfate-azu
Amantidine
Ambap768-94-5
Aminoadamantane
Amixx
AZU, amantadin
Azupharma brand OF amantadine hydrochloride
Azupharma brand OF amantadine sulfate
BIA4304
BIDD:GT0757
Bio-0821
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
C06818
C10H17N
Cerebramed
CHEBI:2618
CHEMBL660
Ciba geigy brand OF amantadine hydrochloride
Ciba-geigy brand OF amantadine hydrochloride
CID2130
D07441
DB00915
Desitin brand OF amantadine hydrochloride
DivK1c_000815
Du pont brand OF amantadine hydrochloride
EINECS 212-201-2
Endantadine
endo Brand OF amantadine hydrochloride
Gen amantadine
Gen-amantadine
GenAmantadine
Gen-Amantadine
Genpharm brand OF amantadine hydrochloride
Hexal brand OF amantadine sulfate
|
HMS1791O12
HMS1989O12
Hormosan brand OF amantadine sulfate
HSDB 3202
Hydrochloride, amantadine
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
infecto Flu
infecto-Flu
InfectoFlu
Infectopharm brand OF amantadine hydrochloride
Infex
Juventus brand OF amantadine hydrochloride
Juventus, amantadina
KBio1_000815
KBio2_000390
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
Krewel brand OF amantadine hydrochloride
L000868
Llorente brand OF amantadine hydrochloride
Llorente, amantadina
Lopac0_000004
Lopac-A-1260
LS-157049
Mantadine
Mantadix
Merz brand OF amantadine sulfate
Midantan
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
Neuraxpharm brand OF amantadine sulfate
neuro Hexal brand OF amantadine sulfate
NINDS_000815
Novartis brand OF amantadine hydrochloride
NSC 341865
NSC341865
NSC83653
Oprea1_248648
OR14310
Orion brand OF amantadine hydrochloride
Pharmascience brand OF amantadine hydrochloride
Pk-merz
Pk-Merz
PMS Amantadine
PMSAmantadine
PMS-Amantadine
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
Ratiopharm brand OF amantadine hydrochloride
Solvay brand OF amantadine hydrochloride
SPBio_000002
SPBio_002273
Spectrum_000030
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Stada brand OF amantadine hydrochloride
Stada brand OF amantadine sulfate
Stada, amantadin
STK298781
Sulfate, amantadine
Symadine
Symmetrel
TCMDC-125869
Thiemann brand OF amantadine hydrochloride
TL8005280
Tregor
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
tricyclo[3.3.1.1(3,7)]Decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]Decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1(3,7)]Decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
Wiregyt
WLN: L66 B6 A B- C 1B ITJ BZ
|
|
4 |
|
Selegiline |
Approved, Investigational, Vet_approved |
Phase 4 |
|
14611-51-9 |
5195 26757 |
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(−)-selegiline
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
Bristol myers squibb brand OF selegiline
Bristol-myers squibb brand OF selegiline
BSPBio_000623
BSPBio_001589
C07245
C13H17N
Carbex
CHEBI:9086
CHEMBL972
CID26757
D03731
DB01037
Deprenalin
Deprenil
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
Hydrochloride, selegiline
Jumex
L-Deprenalin
L-Deprenyl
|
l-E 250
LS-30156
MolPort-000-883-771
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
selegiline
Selegiline
Selegiline (USAN/INN)
Selegiline [INN:BAN]
Selegiline hydrochloride
Selegiline hydrochloride, (R)-isomer
Selegiline hydrochloride, (R,S)-isomer
Selegiline hydrochloride, (S)-isomer
Selegiline Transdermal System (STS) patch
Selegiline valeant brand
Selegiline, (R)-isomer
Selegiline, (R)-Isomer
Selegiline, (R,S)-isomer
Selegiline, (S)-isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
SPBio_002544
STK640578
Tocris-1095
UNII-2K1V7GP655
Valeant brand OF selegiline
Yumex
Zelapar
ZINC19632633
|
|
5 |
|
Rasagiline |
Approved |
Phase 4 |
|
136236-51-6 |
3052776 |
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(1R)-N-propargylindan-1-amine
(1R)-N-Propargylindan-1-amine
(R)-indan-1-yl-prop-2-ynyl-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
2,3-dihydro-N-2-Propynyl-1H-inden-1-amine-(1R)-hydrochloride
AC1MHJZT
AC-723
Azilect
Azilect (TN)
CHEBI:45357
CHEMBL887
CID3052776
D08469
|
DB01367
LS-186771
LS-187776
MolPort-003-850-132
N-2-Propynyl-1-indanamine
NCGC00168774-01
N-Propargyl-1-aminoindan mesylate
RAS
Rasagilina
rasagiline
Rasagiline
Rasagiline (INN)
Rasagiline [INN]
Rasagiline hydrochloride
TVP 101
TVP-101
UNII-003N66TS6T
ZINC19875504
|
|
6 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
7 |
|
Levodopa |
Approved |
Phase 4 |
|
59-92-7 |
6047 |
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-dopa
(-)-Dopa
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
23734-74-9
25525-15-9
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
3 Hydroxy L tyrosine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-dihydroxy-L-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxyphenylalanine (VAN)
3,4-Dihydroxyphenyl-L-alanine
34241-25-3
37830_FLUKA
3-Hydroxy-L-tyrosine
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
BIDD:GT0158
Bio-0575
Biodopa
bmse000322
BPBio1_000059
Brocadopa
BSPBio_000053
BSPBio_002354
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
Cerepap
CHEBI:15765
CHEMBL1009
CID6047
Cidandopa
component of Sinemet
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
DOPA
Dopaflex
Dopaidan
Dopal
Dopal-fher
Dopal-Fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
Eldopal
Eldopar
Eldopatec
EU-0100454
Eurodopa
Helfo DOPA
|
helfo-Dopa
Helfo-Dopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
IDI1_000452
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
IV Levodopa
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L 3,4 Dihydroxyphenylalanine
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
l)-L-alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-dihydroxyphenylalanine
L-3,4-Dihydroxyphenylalanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
L-O-Dihydroxyphenylalanine
L-o-Hydroxytyrosine
Lopac0_000454
Lopac-D-9628
LS-255
L-β-(3,4-dihydroxyphenyl)alanine
Maipedopa
medphano Brand OF levodopa
MLS000028514
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
nchembio.2007.55-comp26
nchembio.89-comp9
ne
NINDS_000452
NSC 118381
NSC118381
Parda
Pardopa
PDSP1_001541
PDSP2_001525
Prestwick_185
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prodopa
Ro 4-6316
Roberts brand OF levodopa
Roche brand OF levodopa
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
Sobiodopa
SPBio_000391
SPBio_001974
Spectrum_000454
Spectrum2_000496
SPECTRUM2300205
Spectrum4_000539
Spectrum5_001899
Syndopa
UNII-46627O600J
Veldopa
Weldopa
β-(3,4-dihydroxyphenyl)alanine
β-(3,4-dihydroxyphenyl)-L-alanine
|
|
8 |
|
Carbidopa |
Approved |
Phase 4 |
|
28860-95-9 |
34359 |
Synonyms:
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamate
(-)-L-a-hydrazino-3,4-Dihydroxy-a-methylhydrocinnamic acid
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamate
(-)-L-alpha-hydrazino-3,4-Dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamate
(-)-L-α-hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoate
(AlphaS)-a-hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoate
(AlphaS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
(S)-(-)-carbidopa
(S)-(−)-carbidopa
(S)-(-)-Carbidopa
(S)-(-)-carbidopa hydrate
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-Carbidopa
(S)-carbidopa hydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C126_SIGMA
C1335_SIGMA
carbidopa
Carbidopa
Carbidopa (anhydrous)
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa Monohydrate
Carbidopa, (R)-isomer
Carbidopa, (S)-isomer
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
|
Carbidopum
Carbidopum [INN-Latin]
carbidopum monohydricum
CCRIS 5093
C-DOPA
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
DB00190
EINECS 249-271-9
EU-0100382
Hadrazino-alpha-methyldopa
HMS2089B12
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionate
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-a-Methyldopahydrazine
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
LS-77199
L-α-methyldopahydrazine
Methyldopahydrazine
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S(-)-CARBIDOPA
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
|
|
9 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 4 |
|
113775-47-6 |
5311068 68602 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
DEXMEDETOMIDINE
Dexmédétomidine
|
Dexmedetomidine (USAN/INN)
Dexmedetomidine hydrochloride
Dexmedetomidinum
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
Precedex
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
10 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
11 |
|
Remifentanil |
Approved |
Phase 4 |
|
132875-61-7 |
60815 |
Synonyms:
132539-07-2 (mono-hydrochloride)
132875-61-7
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
DEA No. 9739
GI 87084B
|
GI 87084X
GI87084B
L001266
LS-115982
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
MolPort-004-286-006
Remifentanil
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanil hydrochloride
Remifentanil monohydrochloride
Remifentanilo
Remifentanyl
Ultiva
Ultiva (TN)
UNII-P10582JYYK
|
|
12 |
|
Acetylcholine |
Approved, Investigational |
Phase 4 |
|
51-84-3 |
187 |
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
13 |
|
incobotulinumtoxinA |
|
Phase 4 |
|
|
|
14 |
|
rimabotulinumtoxinB |
|
Phase 4 |
|
|
|
15 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
16 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
17 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
18 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
19 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
21 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
22 |
|
Antiemetics |
|
Phase 4 |
|
|
|
23 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
24 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
25 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
26 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Protective Agents |
|
Phase 4 |
|
|
|
28 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
29 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
30 |
|
Monoamine Oxidase Inhibitors |
|
Phase 4 |
|
|
|
31 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
32 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
33 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
34 |
|
Carbidopa, levodopa drug combination |
|
Phase 4 |
|
|
|
35 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
36 |
|
Analgesics |
|
Phase 4 |
|
|
|
37 |
|
Anesthetics |
|
Phase 4 |
|
|
|
38 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
39 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
40 |
|
Aromatic Amino Acid Decarboxylase Inhibitors |
|
Phase 4 |
|
|
|
41 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
42 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
43 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
44 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
45 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
46 |
|
Narcotics |
|
Phase 4 |
|
|
|
47 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
48 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
49 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
50 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 379)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie |
Unknown status |
NCT00142259 |
Phase 4 |
|
2 |
The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients |
Unknown status |
NCT01664013 |
Phase 4 |
Nuronox |
3 |
Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study |
Unknown status |
NCT01361373 |
Phase 4 |
L- DOPA;placebo |
4 |
A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study |
Unknown status |
NCT02472210 |
Phase 4 |
Botulinum Toxin |
5 |
The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial |
Unknown status |
NCT03186001 |
Phase 4 |
Abobotulinum toxin A |
6 |
Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults |
Unknown status |
NCT02505802 |
Phase 4 |
BoNT-A injection |
7 |
An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids |
Unknown status |
NCT01583478 |
Phase 4 |
|
8 |
Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone |
Unknown status |
NCT00480844 |
Phase 4 |
Sertindole;Risperidone |
9 |
Pilot Study of the Effect of Botulinum Toxin Type A Treatment on Swallowing in Patients With Cervical Dystonia |
Completed |
NCT01384214 |
Phase 4 |
|
10 |
A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy |
Completed |
NCT01860196 |
Phase 4 |
Meditoxin;Normal saline |
11 |
Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia. |
Completed |
NCT00773253 |
Phase 4 |
Botulinum toxin A |
12 |
RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) |
Completed |
NCT00998660 |
Phase 4 |
|
13 |
An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia |
Completed |
NCT00702754 |
Phase 4 |
|
14 |
An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). |
Completed |
NCT00208091 |
Phase 4 |
Botulinum toxin, type B |
15 |
A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia |
Completed |
NCT00950664 |
Phase 4 |
Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA) |
16 |
Prospective, Single-arm, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 and the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Patients With Cervical Dystonia |
Completed |
NCT00541905 |
Phase 4 |
NT 201 |
17 |
An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment |
Completed |
NCT01486264 |
Phase 4 |
|
18 |
A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism |
Completed |
NCT00331825 |
Phase 4 |
Risperidone and Olanzapine |
19 |
OnabotulinumtoxinA in the Management of Psychogenic Dystonia |
Completed |
NCT02618889 |
Phase 4 |
|
20 |
Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia |
Completed |
NCT00528541 |
Phase 4 |
|
21 |
Synergistic Effects of Neurotoxin and Physical Therapy |
Completed |
NCT02177617 |
Phase 4 |
Botox injection |
22 |
The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia |
Completed |
NCT00950196 |
Phase 4 |
amantadine sulphate |
23 |
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics |
Completed |
NCT00888186 |
Phase 4 |
levodopa/carbidopa |
24 |
Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial |
Completed |
NCT03401515 |
Phase 4 |
Propranolol Hydrochloride 1 MG/ML |
25 |
Golfer's Cramp: Correlation of Wrist Movements and Surface EMG With Putter Movements |
Completed |
NCT02032758 |
Phase 4 |
Propranolol |
26 |
A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy |
Completed |
NCT00432055 |
Phase 4 |
Botulinum toxin type A (Botox);placebo (saline) |
27 |
Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI |
Completed |
NCT03373162 |
Phase 4 |
onabotulinumtoxinA |
28 |
Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications |
Completed |
NCT00443872 |
Phase 4 |
orally disintegrating selegiline (Zelapar) |
29 |
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm: a Randomized, Triple-blind, Placebo-controlled, Cross-over Clinical Trial |
Completed |
NCT03508882 |
Phase 4 |
Botulinum Toxin Type A 100Unit/Vial (Product);Saline Solution for Injection |
30 |
A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia |
Completed |
NCT00114595 |
Phase 4 |
eicosapentaenoic acid |
31 |
Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial |
Completed |
NCT01442610 |
Phase 4 |
Rasagiline;Placebo |
32 |
Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children |
Completed |
NCT00790075 |
Phase 4 |
risperidone |
33 |
Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery |
Recruiting |
NCT03283150 |
Phase 4 |
Remifentanil;Propofol;Dexmedetomidine |
34 |
Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation |
Recruiting |
NCT02480803 |
Phase 4 |
Continuous intrajejunal infusion of levodopa-carbidopa |
35 |
Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia |
Terminated |
NCT00432341 |
Phase 4 |
|
36 |
Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia |
Unknown status |
NCT00169403 |
Phase 3 |
|
37 |
Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia |
Unknown status |
NCT00272246 |
Phase 2, Phase 3 |
|
38 |
Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) |
Unknown status |
NCT00909883 |
Phase 3 |
Botulinum Toxin: Xeomin;Placebo |
39 |
Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus |
Unknown status |
NCT00638066 |
Phase 3 |
botulinum toxin;botulinum toxin A |
40 |
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. |
Completed |
NCT01753310 |
Phase 3 |
Placebo |
41 |
A Prospective, Randomized, Multi-center, Phase III, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Cervical Dystonia |
Completed |
NCT03232320 |
Phase 3 |
Meditoxin;Placebo |
42 |
Open Multicentre Study to Demonstrate the Efficacy and Safety of Botulinum Toxin A (500 Units Dysport®) in the Treatment of Heterogeneous Forms of Cervical Dystonia |
Completed |
NCT00447772 |
Phase 3 |
|
43 |
A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia |
Completed |
NCT00257660 |
Phase 3 |
Placebo |
44 |
A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport® Using 2 mL Dilution In Adults With Cervical Dystonia |
Completed |
NCT01753336 |
Phase 3 |
|
45 |
A Prospective, Randomized, Multi-center, Phase III, Double-Blind, Activi Controlled, Parallel-group Study to Evaliate the Efficacy and Safety of MEDITOXIN® Comparison With BOTOX® in Treatment of Cervical Dystonia |
Completed |
NCT03905304 |
Phase 3 |
|
46 |
Phase II/III Study of Deep Brain Stimulation in Patients With Dystonia |
Completed |
NCT00004421 |
Phase 2, Phase 3 |
|
47 |
Prospective,Randomised, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia |
Completed |
NCT00148889 |
Phase 3 |
|
48 |
Comparative Study of the Efficiency of Zonisamide in Myoclonus Dystonia: A Monocentric , Randomized in Cross Over and Double Blind Study Versus Placebo Study |
Completed |
NCT01806805 |
Phase 3 |
zonegran;placebo |
49 |
Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia |
Completed |
NCT00407030 |
Phase 3 |
incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo |
50 |
A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia |
Completed |
NCT00288509 |
Phase 3 |
|
Cochrane evidence based reviews: dystonia
|